A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/29/2001	WO2001089534A1 Use of metal compounds to treat gastrointestinal infections
11/29/2001	WO2001089533A2 Preparation for stabilizing the protective layer on the epithelium of the cornea or the alveoli
11/29/2001	WO2001089532A1 Preparation of fagopyritols and uses therefor
11/29/2001	WO2001089530A2 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
11/29/2001	WO2001089529A1 Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
11/29/2001	WO2001089527A2 Pharmaceutical composition comprising loratadine and a nasal decongestant
11/29/2001	WO2001089526A1 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
11/29/2001	WO2001089525A1 Combination of cerivastatin with ace inhibitors and the use thereof in medicaments
11/29/2001	WO2001089524A1 Method of promoting smoking cessation
11/29/2001	WO2001089523A1 New pharmaceutical composition and the process for its preparation
11/29/2001	WO2001089522A1 Compositions and methods for administration of pharmacologically active compounds
11/29/2001	WO2001089521A1 Medicinal compositions containing thiophene derivatives
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089519A1 Thromboxane inhibitors, compositions and methods of use related applications
11/29/2001	WO2001089518A1 Method of determining a dosage of anti-oxidant for an individual
11/29/2001	WO2001089517A2 Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors
11/29/2001	WO2001089516A1 Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
11/29/2001	WO2001089515A1 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
11/29/2001	WO2001089514A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
11/29/2001	WO2001089513A1 Use of citrate-containing dialysate for renal dialysis treatment
11/29/2001	WO2001089512A1 Drugs acting on the bronchi
11/29/2001	WO2001089511A2 Superficial therapeutic system containing o-acetylsalicylic acid, for treating skin pain
11/29/2001	WO2001089510A2 Use of an ampa receptor potentiator for the treatment of obesity
11/29/2001	WO2001089508A1 Novel long acting, reversible veterinary sedative and analgesic and method of use
11/29/2001	WO2001089507A1 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
11/29/2001	WO2001089506A1 Medicaments for treating colics
11/29/2001	WO2001089504A1 Tropolone derivatives and pharmaceutical compositions
11/29/2001	WO2001089503A1 Pest treatment composition
11/29/2001	WO2001089502A2 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	WO2001089501A1 Polymerizable compositions and methods of use
11/29/2001	WO2001089500A2 Agents and methods for increasing brain chaperonin levels
11/29/2001	WO2001089499A2 Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
11/29/2001	WO2001089498A2 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
11/29/2001	WO2001089497A2 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/29/2001	WO2001089496A2 Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
11/29/2001	WO2001089495A2 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
11/29/2001	WO2001089494A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
11/29/2001	WO2001089493A2 Compositions containing a benzamide disulfide derivative for treating allergic diseases
11/29/2001	WO2001089492A1 Novel composition
11/29/2001	WO2001089491A1 Novel process
11/29/2001	WO2001089490A1 Dosage of transdermal delivery systems
11/29/2001	WO2001089486A1 Nonoral preparation having three-layer structure
11/29/2001	WO2001089483A1 Tablets and methods for modified release of hydrophilic and other active agents
11/29/2001	WO2001089482A2 Method for preparing microparticles having a selected polymer molecular weight
11/29/2001	WO2001089480A1 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
11/29/2001	WO2001089479A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
11/29/2001	WO2001089478A1 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof
11/29/2001	WO2001089474A2 O/w emulsion
11/29/2001	WO2001089473A1 Pharmaceutical compositions comprising desglymidodrine as an active drug substance
11/29/2001	WO2001089471A2 External skin preparations for suppressing sebum secretion
11/29/2001	WO2001089469A1 Topical composition containing at least one aryl oxime, and method for the preparation thereof
11/29/2001	WO2001089468A1 Use of aryl oximes for the prophylaxis and/or treatment of erythema formation and/or inflammatory reactions of the skin
11/29/2001	WO2001089467A1 Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof
11/29/2001	WO2001089457A2 Thrombopoietin mimetics
11/29/2001	WO2001089451A2 Protease inhibitors
11/29/2001	WO2001089449A2 Phospholipase d effectors for therapy and screening
11/29/2001	WO2001089445A1 Blister package for topiramate tablets
11/29/2001	WO2001089364A2 Hcv variants
11/29/2001	WO2001089319A2 Tryptophan source from plants and uses therefor
11/29/2001	WO2001089303A1 Methods of modulating the activity of mura
11/29/2001	WO2001070695A8 Pyridine derivatives as inhibitors of p38
11/29/2001	WO2001066096A3 Compositions for prevention and treatment of dementia
11/29/2001	WO2001060835A8 Purine derivatives
11/29/2001	WO2001060810B1 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
11/29/2001	WO2001055115A8 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/29/2001	WO2001051497A8 Novel bisphosphonates and uses thereof
11/29/2001	WO2001049674A3 Glycosidase inhibitors and preparation thereof
11/29/2001	WO2001046150A3 Quinolone compounds for use in treating viral infections
11/29/2001	WO2001044465A3 Therapeutically useful synthetic oligonucleotides
11/29/2001	WO2001042272A3 Eplerenone crystalline form exhibiting enhanced dissolution rate
11/29/2001	WO2001041756A8 Method and composition for treatment of ischemic neuronal reperfusion injury
11/29/2001	WO2001040451A3 Masp-3, a complement-fixing enzyme, and uses for it
11/29/2001	WO2001040309A3 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
11/29/2001	WO2001038566A3 Screening method for candidate drugs
11/29/2001	WO2001037816A3 Coating of tablet cores
11/29/2001	WO2001035950A3 Benzamide therapeutics and methods for treating inflammatory bowel disease
11/29/2001	WO2001035902A9 Stabilized thyroxine compounds
11/29/2001	WO2001030780A3 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
11/29/2001	WO2001029018A3 Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
11/29/2001	WO2001028996A3 Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
11/29/2001	WO2001028567A3 Aminoalkylenephosphonates for treatment of bone disorders
11/29/2001	WO2001028544A3 Dialysis solution including polyglycol osmotic agent
11/29/2001	WO2001027304A3 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
11/29/2001	WO2001025433A3 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
11/29/2001	WO2001023590A3 22196, a novel human aminopeptidase
11/29/2001	WO2001019776A3 Novel derivatives of dicarboxylic acid having pharmaceutical properties
11/29/2001	WO2000073469A3 Protein kinases
11/29/2001	WO2000061597A9 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
11/29/2001	WO2000061162A9 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
11/29/2001	WO2000059882A9 Anticancer calcium channel blockers
11/29/2001	WO2000056298A9 Treatment of lyme disease with polysulfated glycosaminoglycan formulations
11/29/2001	WO2000055159A3 Substituted aza-oxindole derivatives
11/29/2001	WO2000051586A3 Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound
11/29/2001	WO2000047104A9 Antagonists of hmg1 for treating inflammatory conditions
11/29/2001	WO2000041473A3 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
11/29/2001	WO2000040210A3 Topical compositions comprising protected functional thiols
11/29/2001	WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists
11/29/2001	WO2000038666A3 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
11/29/2001	WO2000034258A3 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
11/29/2001	WO2000010548A3 19-nor-vitamin d3 compounds with calcemic activity

1 ... 5955 5956 5957 5958 5959 5960 5961 5962 5963 5964 5965 5966 5967 5968 5969 5970 5971 5972 5973 5974 5975 ... 7860